Since GBM tumors express high levels of PD-L1, which was shown to be linked to shorter survival, we decided to combine SCIB1 ImmunoBody® vaccination with PD-1 blockade to assess the time-to-death of humanized C57BL/6 HHDII/DR1 mice harboring intracranial B16HHDII/DR1 tumors expressing TRP-2 and gp100. This evidence concerns the gene CD274 and glioblastoma.